Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

'Real-life' persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study

Alain Michils, Olivier Vandenplas, Guy Brusselle, Christopher Lee, Jan Van Schoor, Sandra Gurdain, Christine Hermans, Stefaan Vancayzeele, Karen MacDonald, Ivo Abraham
European Respiratory Journal 2011 38: p3959; DOI:
Alain Michils
1Respiratory Medicine, ULB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Vandenplas
2Respiratory Medicine, UCL, Yvoir, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy Brusselle
3Respiratory Medicine, UGent, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Van Schoor
6Medical Department, Novartis Pharma, Vilvoorde, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Gurdain
6Medical Department, Novartis Pharma, Vilvoorde, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Hermans
6Medical Department, Novartis Pharma, Vilvoorde, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefaan Vancayzeele
6Medical Department, Novartis Pharma, Vilvoorde, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen MacDonald
4Effectiveness Research, Matrix45, Earlysville, VA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivo Abraham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Omalizumab (OMA) treatment has been shown to be effective in patients with severe allergic asthma (SAA), but published data beyond the first year of treatment are scarce.

Objectives: To examine the persistence rate (PR), to identify reasons for discontinuation and to determine the response rate (RR) and the clinical effectiveness beyond the first year of OMA treatment.

Methods: Of 105 patients who were on OMA treatment at the end of the 52w observational PERSIST study (Respir Med 2009; 103: 1633), 53 (51%) participated in this study. A retrospective medical chart analysis was performed at approx. 16, 52, and 68w after the end of the PERSIST study (up to 120w of treatment). Measurements included PR, physician-rated Global Evaluation of Treatment Effectiveness (GETE), Asthma-related Quality of Life Questionnaire (AQLQ), and systemic glucocorticosteroid (sGCS) use, emergency room (ER) visits and hospitalizations for severe exacerbations.

Results: The PR at 120w was 84.9%. Treatment was discontinued in 3 cases by patient decision (1 relocation, 1 AE, 1 non-compliance with office visits), in 3 patients by joint patient/physician decision (2 complete asthma control, 1 AE) and in 2 patients due to non-OMA related death. Where data were available, RR (good+excellent GETE) was >85%. Absolute change of ≥0.5 point in AQLQ score remained >90% from 0w up to 120w; less than 18.9% of patients required sGCS, there were no ER visits and only 1 hospitalization during the evaluation period.

Conclusions: These preliminary results indicate a high PR with OMA beyond the first year of treatment under “real-life” conditions in SAA patients in Belgium.

  • © 2011 ERS
Previous
Back to top
Vol 38 Issue Suppl 55 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
'Real-life' persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
'Real-life' persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study
Alain Michils, Olivier Vandenplas, Guy Brusselle, Christopher Lee, Jan Van Schoor, Sandra Gurdain, Christine Hermans, Stefaan Vancayzeele, Karen MacDonald, Ivo Abraham
European Respiratory Journal Sep 2011, 38 (Suppl 55) p3959;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
'Real-life' persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study
Alain Michils, Olivier Vandenplas, Guy Brusselle, Christopher Lee, Jan Van Schoor, Sandra Gurdain, Christine Hermans, Stefaan Vancayzeele, Karen MacDonald, Ivo Abraham
European Respiratory Journal Sep 2011, 38 (Suppl 55) p3959;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Effects of hydrocortisone on acute beta-blocker and histamine induced bronchoconstriction
  • Risks of diabetes mellitus and hyperglycaemic adverse events in patients with asthma taking inhaled corticosteroids
  • Increased incidence of pulmonary embolism in severe asthma
Show more 413. Asthma management and response

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society